Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine in Treatment Resistant Depression
NCT07307768Phase 1Withdrawn
- Sponsor
- Soterix Medical
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ketamine in treatment-resistant depression (TRD) (3 arms), sponsored by Soterix Medical. Primary endpoint: Hamilton Depression Rating Scale 22 at 72 hours. Planned start Dec 2025; status: withdrawn.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT07307768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07307768.